eli lilly glp-1 medications portfolio set to leapfrog Novo Nordisk in weight-loss drug race Top Obesity and Diabetes Medications

More people discontinued orforglipron during the trial than those who stopped taking semaglutide, too

What raises concerns are some of the recent reports of serious ADRs associated with GLP-1RAs: (i) Pfizers disclosure of elevated aminotransferases in users of lotiglipron (a novel oral GLP-1RA) is indicative of hepatocellular injury [11]

For 503B outsourcing facilities, no equivalent safe harbor appears to apply, and enforcement grace periods that had been in place through early 2026 are expiring, leaving bulk compounders of GLP-1s in a substantially more precarious legal position

However, he added, It would be better if we figured out a national way to improve affordability across the broad set of patients.